BioTime Inc (BTX)

3.32
AMEX : Health Care
Prev Close 3.39
Day Low/High 3.23 / 3.42
52 Wk Low/High 2.02 / 4.10
Avg Volume 270.90K
Exchange AMEX
Shares Outstanding 103.39M
Market Cap 350.50M
EPS -0.60
P/E Ratio 14.74
Div & Yield N.A. (N.A)

Latest News

BioTime Co-CEO Dr. Michael D. West To Chair Cell Therapy Track At World Precision Medicine Congress USA 2016

BioTime Co-CEO Dr. Michael D. West To Chair Cell Therapy Track At World Precision Medicine Congress USA 2016

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that Co-Chief Executive Officer Michael D.

BioTime, Inc. Reports Third Quarter Results And Recent Clinical Progress

BioTime, Inc. Reports Third Quarter Results And Recent Clinical Progress

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent cell-based technologies, today reported financial results for the third quarter ended September 30, 2016, and...

Data From BioTime's Renevia Pivotal Trial In HIV-Associated Facial Liopatrophy To Be Presented At The 14th Annual IFATS Meeting On November 17

Data From BioTime's Renevia Pivotal Trial In HIV-Associated Facial Liopatrophy To Be Presented At The 14th Annual IFATS Meeting On November 17

BioTime, Inc. (NYSE MKT:BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that an abstract evaluating Renevia ® in 'run-in' patients with...

BioTime Appoints Industry Veteran Jim Knight As Senior Vice President, Head Of Corporate Development

BioTime Appoints Industry Veteran Jim Knight As Senior Vice President, Head Of Corporate Development

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that the company has appointed Jim Knight as Senior Vice President, Head of...

BioTime, Inc. To Announce Third Quarter Results On November 3, 2016

BioTime, Inc. To Announce Third Quarter Results On November 3, 2016

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company with a focus on pluripotent stem cell technologies, today announced that it will release third quarter financial and operating results on Thursday,...

First Patient Cohort Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016

First Patient Cohort Data From BioTime's OpRegen® Clinical Trial In Dry-AMD To Be Presented At ISOPT Clinical Symposium On December 2, 2016

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technologies, today reported that data from the first patient cohort of the Phase I/IIa clinical...

LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive MHealth Innovation

LifeMap Solutions Joins Medidata AppConnect Partner Program To Drive MHealth Innovation

LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO), the leading provider of cloud-based solutions for clinical research.

BioTime To Present At The BIO Investor Forum

BioTime To Present At The BIO Investor Forum

BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that Adi Mohanty, Co-Chief Executive Officer, will be presenting at the BIO Investor...

BioTime To Webcast Presentation At The Ladenburg Thalmann 2016 Healthcare Conference

BioTime To Webcast Presentation At The Ladenburg Thalmann 2016 Healthcare Conference

BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the Ladenburg Thalmann 2016 Healthcare Conference...

BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries

BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial In Patients With Complete Cervical Spinal Cord Injuries

BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim...

BioTime To Present At Two Upcoming Investor Conferences

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT: BTX), a clinical stage biotechnology company with a focus on pluripotent stem cell technology, today announced that it will be presenting at the following investor conferences: ...

BioTime Announces Issuance Of 31 New Patents To Strengthen Its Patent Portfolio In Regenerative Medicine

BioTime Announces Issuance Of 31 New Patents To Strengthen Its Patent Portfolio In Regenerative Medicine

BioTime, Inc. (NYSE MKT:BTX) today announced the issuance of 31 new patents between July 3, 2015 and August 3, 2016 that are owned by or licensed to BioTime, or its family of companies.

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. Reports Second Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the second quarter ended June 30, 2016 and provided a...

BioTime, Inc. To Report Second Quarter Results On August 9, 2016

BioTime, Inc. To Report Second Quarter Results On August 9, 2016

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that it will release second quarter financial and operating results on Tuesday,...

BioTime, Inc. Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option

BioTime, Inc. Announces Full Exercise And Closing Of Underwriters' Over-Allotment Option

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced that the underwriters of BioTime, Inc.

BioTime Presents Online Resource For Applying Artificial Intelligence To Stem Cell Biology At Mensa 2016 Annual Gathering

BioTime Presents Online Resource For Applying Artificial Intelligence To Stem Cell Biology At Mensa 2016 Annual Gathering

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr.

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. Announces Closing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced...

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. Announces Pricing Of Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public...

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. Announces Proposed Public Offering Of Common Stock

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its...

BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD

BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD

BioTime, Inc. (NYSE MKT and TASE: BTX) and Cell Cure Neurosciences Ltd.

BioTime Announces $2.2 Million Grant For Further Development Of Dry-AMD Program

BioTime Announces $2.2 Million Grant For Further Development Of Dry-AMD Program

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary Cell Cure Neurosciences Ltd.

BioTime To Present At The Jefferies 2016 Global Healthcare Conference

BioTime To Present At The Jefferies 2016 Global Healthcare Conference

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare...

BioTime To Present At Two Upcoming Investor Conferences

BioTime To Present At Two Upcoming Investor Conferences

BioTime, Inc. (NYSE MKT and TASE: BTX) announced that Co-Chief Executive Officer Michael D.

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. Reports First Quarter Results And Recent Corporate Accomplishments

BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and...

BioTime Co-CEO Dr. Michael West Presents At Biomedical Innovation For Healthy Longevity, International Conference

BioTime Co-CEO Dr. Michael West Presents At Biomedical Innovation For Healthy Longevity, International Conference

BioTime, Inc. (NYSE MKT:BTX) announced that Co-Chief Executive Officer Michael D.

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development To Meet The Needs Of Medical, Research, And Commercial Partners

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development To Meet The Needs Of Medical, Research, And Commercial Partners

LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX) and co-developer of ResearchKit-enabled app Asthma Health, today announced a new service to develop custom smartphone apps and research...

BioTime Co-CEO Dr. Michael West To Present At Stem Cells In Drug Discovery 2016 In Cambridge, UK

BioTime Co-CEO Dr. Michael West To Present At Stem Cells In Drug Discovery 2016 In Cambridge, UK

BioTime, Inc. (NYSE MKT: BTX) today announced that Co-Chief Executive Officer Michael D.

5 Hated Stocks Poised to Turn Around on Earnings

5 Hated Stocks Poised to Turn Around on Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.